.jpg)
.png)
All
Welcome to the Scientific Sessions issue of the LipidSpin — this year sponsored by the Northeast Lipid Association (NELA). We have had a lot of fun putting this issue together, and hope that you will enjoy reading this issue just as much. The theme for this issue is “Debunking Common Myths in... more
The Journal of Clinical Lipidology received its 2012 impact factor of 2.741 in June 2013. This is a considerable increase since its most recent impact factor of 1.583 was announced in June 2012. The Editor-in-Chief, Virgil Brown, MD, would like to thank the Associate Editors and the Editorial Board... more
In 2009, a 75-year-old Tsimane man and his wife awoke and went out into the rain forest around their home in the Amazonian lowlands of Bolivia to collect jajata, a palm like plant used to make roofing. Walking home in the afternoon, he collapsed to the ground, unconscious. His wife shook him and... more
Testosterone is a predominantly male hormone responsible for virilization of the external male genitalia during embryonic development, promotion of somatic growth, and secondary sexual characteristics in puberty, normal sexual function and libido in both males and females, and promotion of bone... more
Wednesday, February 10, 2016 6:00 PM Presented by: Sotirios “Sam” Tsimikas, MD, FACC Cardiovascular Franchise Leader Vice President of Clinical Development IONIS Pharmaceuticals, Inc “Lipoprotein(a);... more
The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” Michelangelo Buonarroti Along with the NLA Scientific Sessions, the summer also brings the anticipation of the Prescription Drug User Fee Act (... more
American Association of Clinical Endocrinologists While you take advantage of our many informational and supportive services, please take time to gain insight into our organization by browsing through the information provided on this website. We are confident that we offer clinical... more
Introduction It’s been over 20 years since the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial1 ushered in the initiation of aggressive LDL-C lowering therapy before hospital discharge for acute coronary syndrome (ACS). Three years later, the Intensive versus... more
With spring time comes the NLA Annual Sessions and the beginning of a new term for officers and board members. I could not be more excited to serve as president for 2017-2018, and do so with a strong group of dedicated leaders that make the job both productive and enjoyable. What better way to... more
View the May 2019 SELA E-Newsletter by clicking here.